港股異動 | 中國科培(1890.HK)大漲逾10%破頂 中期純利大增超3成
格隆匯8月31日丨中國科培(01890.HK)急升至10.11%創新高,現報7.19港元,暫成交2171萬港元,最新總市值144.9億港元。中國科培8月 28日公告,上半年集團實現收益4.19億元人民幣(單位下同),同比增長16.6%;母公司擁有人應占溢利3.21億元,同比增長31.1%;核心純利3.11億元,同比增長27.0%;每股盈利0.16元。收益增長主要來自學費收益及住宿費收益。招商證(香港)曾指出,預計公司20-22財年核心淨利潤年複合增長率將達到26%,資產負債表穩健,為更多併購做好準備。看好估值上調前景,首次覆蓋並給於買入評級,目標價為8.3港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.